Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.48 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14595304 | 0.82 | ALDH1A1 (0.52) | HDAC1HDAC6ALDH1A1APPGAA | |
| SCHEMBL4921939 | 0.82 | F7 (0.52) | HDAC1HDAC6ALDH1A1APPGAA | |
| SCHEMBL15588644 | 0.79 | F7 (0.53) | HDAC1HDAC6ALDH1A1APPGAA | |
| SCHEMBL16791193 | 0.79 | ALDH1A1 (0.49) | HDAC1HDAC6ALDH1A1APPGAA | |
| SCHEMBL8481624 | 0.77 | ALDH1A1 (0.56) | HDAC1HDAC6ALDH1A1APPGAA | |
| SCHEMBL9215228 | 0.77 | POLB (0.50) | HDAC1HDAC6ALDH1A1APPGAA | |
| SCHEMBL455628 | 0.77 | NAMPT (0.56) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL22575262 | 0.76 | HCAR3 (0.47) | HDAC1HDAC6GAAHCAR3LMNA | |
| SCHEMBL12209496 | 0.76 | ALDH1A1 (0.54) | HDAC1HDAC6ALDH1A1APPGAA | |
| Hydrochloric Acid SCHEMBL8485517 | 0.76 | ALDH1A1 (0.54) | HDAC1HDAC6ALDH1A1APPGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042731-A1 | (2,4-DICHLOROPHENOXY)ACETIC ACID ANALOGS | CORTEVA AGRISCIENCE LLC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4363415-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2025-12-10 | — | — | EP | disclosed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| US-20240279217-A1 | Heterocyclic compounds for the treatment of tuberculosis | TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) | 2024-08-22 | — | — | US | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| EP-4363415-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | Tecnimede, Sociedade Técnico-Medicinal, SA (PT) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024031002-A1 | (2,4-DICHLOROPHENOXY)ACETIC ACID ANALOGS | CORTEVA AGRISCIENCE LLC (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-20040067940-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | BIOREX RESEARCH & DEVELOPMENT CO. | 2004-04-08 | — | — | US | disclosed |
| US-20040019103-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | BIOREX RESEARCH & DEVELOPMENT CO. | 2004-01-29 | — | — | US | disclosed |
| US-6653326-B1 | For example, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-3-pyridinecarboximidoyl chloride maleate; inducing gene expression of an eukaryotic cell under physiological stress; antiallergens; autoimmune diseases; cardiovascular disorders | BIOREX RESEARCH & DEVELOPMENT CO. (HU) | 2003-11-25 | — | — | US | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| EP-0801649-B1 | HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF | BIOREX KUTATO FEJLESZTOE KFT (HU) | 2002-08-07 | — | — | EP | disclosed |
| EP-0801649-A2 | HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF | BIOREX KUTATO ES FEJLESZTÖ RT. (HU) | 1997-10-22 | — | — | EP | disclosed |
| WO-1997016439-A1 | HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF | Biorex Kutató és Fejlesztó Rt. (HU) | 1997-05-09 | — | — | WO | disclosed |
| US-4305948-A | N-Hydroxy-1,2-dihydro-2-oxo-5-(pyridinyl)-nicotinimidamide and their cardiotonic use | STERLING DRUG INC. (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279217-A1 | Heterocyclic compounds for the treatment of tuberculosis | SDHA, NQO1, FNTB | HDAC1 165/4885HDAC6 150/4885ALDH1A1 568/4885 |
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP1, USP18 | HDAC1 153/4885HDAC6 100/4885ALDH1A1 494/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | HDAC1 3745/4885HDAC6 4244/4885ALDH1A1 3915/4885 |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | HDAC1 3745/4885HDAC6 4244/4885ALDH1A1 3915/4885 |
| US-20040019103-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | HSPE1, HSF1, HSPA1A | HDAC1 2911/4885HDAC6 591/4885ALDH1A1 641/4885 |
| US-20260042731-A1 | (2,4-DICHLOROPHENOXY)ACETIC ACID ANALOGS | DDT, AADAC, HACL2 | HDAC1 134/4885HDAC6 131/4885ALDH1A1 264/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | HDAC1 460/4885HDAC6 1930/4885ALDH1A1 133/4885 |
| US-20040067940-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | HSPE1, HSF1, HSPA1A | HDAC1 2911/4885HDAC6 591/4885ALDH1A1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.